Elizabeth Freedman, MD
Family Medicine · East Granby, CTNPI 1154308211
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,582 of the $5,223 with a category attached, or 87.7%. It is spread thinly across 35 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,637 and has fallen 72.3% since, to $453 in 2025. Among family medicine clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$687
- Supreme Orthopedic Systems, LLC$641
- AstraZeneca$516
- Lilly USA, LLC$428
- GSK$322
- plus $2K from 29 others
What the payments were for
- Travel & lodging$64112%
- Food & beverage$4,58288%
- Education$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $1,014 |
| Novo Nordisk | 34 | $687 |
| Supreme Orthopedic Systems, LLC | 1 | $641 |
| AstraZeneca | 26 | $516 |
| Lilly USA, LLC | 23 | $428 |
| GSK | 17 | $322 |
| Pfizer | 13 | $288 |
| Boehringer Ingelheim | 7 | $157 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $151 |
| Abbott | 4 | $92 |
| Exact Sciences | 4 | $87 |
| Sanofi-aventis U.S. LLC | 5 | $86 |
| Astellas Pharma US Inc | 3 | $59 |
| Merck | 4 | $55 |
| Ultragenyx Pharmaceutical Inc. | 3 | $51 |
| Amarin Pharma, Inc. | 3 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $47 |
| Teva Pharmaceuticals USA, Inc. | 3 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Medtronic(2 entities) | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 1 | $37 |
| Kyowa Kirin, Inc. | 2 | $35 |
| Mylan Specialty L.p. | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Ardelyx, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Novartis | 1 | $17 |
| Amgen | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Cranial Technologies, Inc | 1 | $13 |
How this compares
$5,223 in reported general payments places this provider in the 90th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $57,015 |
| FarxigaDapagliflozin Propanediol | 25 | $21,581 |
| EliquisApixaban | 17 | $13,843 |
| JardianceEmpagliflozin | 13 | $11,397 |
| BelsomraSuvorexant | 18 | $7,388 |
| SynthroidLevothyroxine Sodium | 33 | $2,848 |
| Atorvastatin Calcium | 152 | $1,629 |
| Valsartan | 65 | $1,146 |
| Duloxetine Hcl | 52 | $1,056 |
| Levothyroxine Sodium | 125 | $993 |
| Rosuvastatin Calcium | 152 | $958 |
| Gabapentin | 50 | $953 |
| Lisinopril | 79 | $873 |
| Escitalopram Oxalate | 85 | $857 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $687 | $57,01548 claims |
| AstraZenecaFarxiga | $516 | $21,58125 claims |
| PfizerEliquis | $288 | $13,84317 claims |
| Boehringer IngelheimJardiance | $157 | $11,39713 claims |
| MerckBelsomra | $55 | $7,38818 claims |
| AbbVieSynthroid | $1,014 | $2,84833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family medicine providers in Connecticut.
Other family medicine in East Granby
- Edward EwaldEast Granby$6K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
- Helar CamposNew London$29K
- Kristin GianniniVernon$28K
- Sanjeev RaoBridgeport$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.